Recombinant p. falciparum merozoite protein-142 vaccine
CA 2462946 C · Owner: Voss, Gerald · Inventors: Cohen, Joe D.; Lyon, Jeffrey A.; Voss, Gerald
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production and as a vaccine.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 25, 2002 and granted April 29, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 25, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 25, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.